Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... 1 study and demonstrated declines in circulating tumor cells and evidence of reduction in tumor markers. Eli Lilly and Company recently ... data confirming that LY2181308 penetrates tumor tissue and reduces survivin mRNA and protein ...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

... the bone complications, or SREs, caused by the tumor are reduced or delayed. The primary and secondary ... needs. Amgen is studying denosumab in numerous tumor types across the spectrum of cancer induced bone ... patients and as high as 75 percent in solid tumor patients. With bone metastases the growing ...

OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer

... and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, ... to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside ...

Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy

... from Self-Renewing, Proliferating Autologous tumor Cells as Patient-Specific Anti-Tumor Vaccines in ... the patient's immune system to react against tumor stem cells or early progenitor cells that can ... observed following vaccination with irradiated tumor cells in 48 melanoma patients in a previous trial ...

National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness

... preclinical studies to provide clues into tumor susceptibility mechanisms for brostallicin, a ... trabectedin, the NCI research indicates that the tumor cell DNA damaging effects of brostallicin are enhanced by high tumor glutathione levels, a hallmark of drug-resistant ...

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

... with Eric Holland, MD, PhD, Director of the Brain tumor group at Memorial Sloan-Kettering Cancer Center, ... that single agent perifosine not only induced tumor regression and delayed tumor growth, but that perifosine also improved the ...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

... the bone complications, or SREs, caused by the tumor are reduced or delayed. The primary and ... needs. Amgen is studying denosumab in numerous tumor types across the spectrum of cancer induced bone ... the bone around the tumor. The damage the tumor has caused to the bone can result in a number of ...

Alfacell Provides Shareholder Update

... can be widely used in therapy of different tumor types, including most common types such as cancer ... Onconase to Cisplatin significantly increased the tumor growth inhibition compared to Cisplatin or Onconase alone, and in the tumor model most resistant to platinum, Onconase ...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

... - Afinitor significantly reduced tumor size by 50% or more in one out of three patients ... experienced a 50% or greater reduction in tumor size. This 33% overall response rate (ORR) is defined as complete or partial tumor shrinkage (95% confidence interval: 26-41%). The ...

Access Pharmaceuticals Announces Publication of Thiarabine Combination Data

... CEO. "Thiarabine has been in two Phase 1/2 solid tumor trials and was shown to have significant ... and their combinations were tested in five tumor models. "In all cases, thiarabine demonstrated superior tumor growth inhibition than clofarabine when the ...

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

... - 71% Objective tumor Response in Combination with Docetaxel in Advanced Breast Cancer - - 65% Objective tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer - - 64% Objective tumor Response in Combination with ...

Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer

... by a factor of 1.5 to 2.0, OPAXIO increases tumor specific radiation cell kill by a factor of 7.2 ... conjugate is a potent enhancer of tumor radiocurability , Int'l J. Radiat. Oncol. Biol. ... accumulation of paclitaxel poliglumex in tumor tissue with continual slow release of the active ...

CuraGen Updates CR011-vcMMAE Data at ASCO

... disease. Fifty percent (50%) of patients showed tumor shrinkage. Toxicities were similar to those ... progression-free survival (PFS) was 4.4 months. tumor shrinkage was observed in 58% of patients, and 20 ... PFS. Additionally, in a subset of patients with tumor biopsies, high levels ...

Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program

... and from preclinical studies of XERECEPT in brain tumor models. NTI sold the worldwide rights and ... with limited treatment options. The preclinical tumor model studies indicate that XERECEPT(R) also has ... percent of these patients showing reductions in tumor size of 50 percent or greater. Celtic Pharma ...

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

... clinical benefit as determined by reductions in tumor volume, reductions in tumor markers, and improvement in cancer-related ... were demonstrated in patients with a variety of tumor types including melanoma, renal cell, ovarian and ...

Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting

... on clinical advances for its carfilzomib solid tumor program in an oral presentation at the 2009 ... of the proteasome for treatment of solid tumor patients. The compound's unique characteristics ... the Phase 1b/2 clinical trials of relapsed solid tumor patients were presented by Dr. Rosen at the 2009 ...

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

... Phase I data on SF1126 in 36 advanced solid tumor patients. The majority of patients were heavily ... disease for 20 weeks (5 mos.). These specific tumor types are associated with aberrations of the PI3K ... outcomes. Pharmacodynamic analysis of tumor tissue confirmed inhibition of the PI3K pathway ...

Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506

... inhibitor currently being studied in multiple tumor types. These data were presented at the 45th ... Phase III clinical development program in various tumor types for this new drug candidate." ... into a Phase III trial in one of the multiple tumor types that may be responsive to BAY 73-4506." ...

Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

... survival (PFS) and disease control measured by tumor response rate. New data derived by three ... the safety and efficacy (assessed by objective tumor response, PFS and overall survival) of ... expect those data later this year. The new PFS, tumor response and neurotoxicity data provide the ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... of treatment, Afinitor(R) stabilized or reduced tumor size in 61% of patients with advanced liver ... These studies provide new research on multiple tumor types and rare cancers. To view the ... to placebo, more than doubled time without tumor growth (15.6 months vs. 5.9 months) and reduced ...

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

... that are expressed on the surface of new tumor vasculature and within the tumor compartment. In preclinical xenograft models ... is observed with high frequency in a variety of tumor types. PI3K signaling through its downstream ...

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting

... prior to surgery. Patients who present with tumor containing lymph nodes are particularly difficult ... by direct injection, at three dose levels, into tumor containing lymph nodes in combination with ... low dose patient developed a new primary tumor post treatment. OncoVEX GM-CSF was detected in ...

AlphaVax Announces Promising Results in Melanoma Studies

... vector particles (VRP) encoding melanoma-specific tumor antigens to reduce melanoma tumor burden in a state-of-the-art murine melanoma ... melanoma includes surgical removal of the tumor tissue, followed by chemotherapy and/or radiation ...

Melanoma and Pregnancy: What Every Woman Needs to Know About the Risks, Prognosis

... for melanoma is based on three variables -- tumor thickness, presence or absence of ulceration, and ... lymph nodes or other organs. For example, if a tumor is less than 1 mm in depth (which is considered a ... of the disease), no ulceration is present in the tumor (meaning the top layer of the skin when examined ...

Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients

... patients in this cohort demonstrated an objective tumor response according to RECIST criteria. These ... objectives of the study include measuring time to tumor progression, duration of response, overall ... Patients in the study are evaluated regularly for tumor response according to RECIST criteria. Patients ...

Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies

... that in vitro, anti-PS antibodies stimulate the tumor microenvironment to recruit monocytes and other immune cells to the tumor with resulting anti-tumor effects, most likely ... the role of anti-PS antibodies in mediating tumor cell cytotoxicity and the tumor microenvironment, ...

New Body of Research Suggests Statin Use Benefits Multiple Areas of Urologic Health

... at radical prostatectomy, including adverse tumor features and lower risk of positive surgical ... Association between statins, obesity and prostate tumor inflammatory infiltrate in men undergoing radical ... tumor. Obesity may be associated with increased tumor inflammation, and with more aggressive prostate ...

Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint

... patients with melanoma, a historically difficult tumor to treat," said Todd Yancey, M.D., vice president ... Mechanism Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has ...

Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model

... Mouse Equivalent to the Human Antibody Inhibited tumor Growth in a Prostate Cancer Model by More than ... cells that line the blood vessels of tumors (the tumor vascular endothelium), creating a specific target ... mobilize the body's immune system to destroy the tumor and ...

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

... are not active in colorectal cancer patients with tumor cells harboring mutations in KRAS and BRAF ... 0.1 microgram/kilogram were sufficient to prevent tumor growth from mutated human colorectal cancer ... a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting ...

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer

... responses. In addition, MDX-1338 also reduced tumor growth in acute myelogenous leukemia and lymphoma ... MDX-1110, an anti-Fucosyl-GM1 antibody in a SCLC tumor model (Abstract #838) Fucosyl-GM1 is a ... complement-dependent cytotoxicity) for killing tumor cells. Additionally, MDX-1110 showed a favorable ...

First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept

... (p<0.03 vs. baseline). In comparison, tumor growth was observed across the saline control, ... cisplatinum arms. In addition, in the EP-100 arm tumor volumes, weights and CA125 (a clinical biomarker ... treated tumors became necrotic, lacking viable tumor cells after treatment. EP-100 was well tolerated ...

Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies

... Suppressing Effects of Tumors by Changing the tumor Microenvironment and Mobilizing Key Components of ... selectively destroy the blood vessels supporting tumor growth and spread and also to reverse the ability ... facilitate an important cytokine shift in the tumor environment that subsequently encourages multiple ...

Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin

... to the genetic configuration in a patient's tumor that makes it susceptible to a specific drug thus ... targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA ... interfering with DNA division and leading to tumor cell death. More than 200 patients have been ...

New Imaging Analysis Predicts Brain Tumor Survival

... or MRI, protocol to monitor changes over time in tumor blood volume within individual voxels of the ... researchers to see specific areas in which tumor blood volume increased or decreased, that may ... and the relative cerebral blood flow of the tumor to analyze voxel-wise changes among the serial ...

Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial

... Carboplatin + Paclitaxel Achieved an Objective tumor Response - - Patient Dosing Initiated in ... cell lung cancer (NSCLC) achieved an objective tumor response according to RECIST criteria, after ... very pleased to see these additional objective tumor responses in this difficult-to-treat cancer ...

Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier

... may turn on certain genes as a strategy by the tumor to adapt to the therapy and become resistant to ... such as RAD51 as an adaptive strategy to help the tumor repair the DNA damage done by these agents. In ... genes), effectively blocking the ability of the tumor to repair its damaged DNA, sensitizing ...

Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib

... - Afinitor more than doubled time without tumor growth and reduced the risk of disease ... mTOR, a protein inside the cell that controls tumor cell division and blood vessel growth - ... with placebo, more than doubled the time without tumor growth or death in patients with advanced kidney ...

Another LNA-based RNA Inhibitor Enters Clinical Trials

... EZN-3042 inhibited Survivin expression and tumor growth. It also potentiated the ... delivery of RNA antagonist oligonucleotides in tumor cells and in mice" "EZN-2208, a novel ... specifically inhibits the growth of AR-positive tumor cells" "The antitumor activity of ...

MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer

... study of liver stem cells and liver cancer. tumor tissues are composed of a mixture of cells with some tumor cells exhibiting stem cell-like properties ... therapies that result in cytoreduction and thus tumor regression, the control of cancer over a longer ...